Chimeric scFv/γ receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules

International Journal of Cancer

Volumn 77, Issue 2, 1998, Pages 181-187

  Weijtens, M E M ^a   Willemsen, R A ^a   Van Krimpen, B A ^a   Bolhuis, R L H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD18 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CELL ADHESION; CELL INTERACTION; CYTOLYSIS; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD11; ANTIGENS, CD18; ANTIGENS, CD2; ANTIGENS, CD3; ANTIGENS, CD58; ANTIGENS, NEOPLASM; CARCINOMA, RENAL CELL; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN FRAGMENTS; INTERCELLULAR ADHESION MOLECULE-1; MELANOMA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0043128070     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980717)77:2<181::AID-IJC2>3.0.CO;2-M     Document Type: Article

References (38)

1. ALTOMONTE, M., GLOGHINI, A., BERTOLA, G., GASPAROLLO, A., CARBONE, A., FERRONE, S. and MAIO, M., Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res., 53, 3343-3348 (1993).
2. BECKER, J.C., TERMEER, C., SCHMIDT, R.E. and BROECKER, E.B., Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/ tumor interaction. J. Immunol., 151, 7224-7232 (1993).
3. BLANK-VOORTHUIS, C.J.A.C., BRAAKMAN, E., RONTELTAP, C.P.M., TILLY, B.C., STURM, E., WARNAAR, S.O. and BOLHUIS, R.L.H., Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3. J. Immunol., 151, 2904-2914 (1993).
4. BOLHUIS, R.L.H., GRAVEKAMP, C. and VAN DE GRIEND, R.J., Cell-cell interactions. Clin. Immunol. Allergy, 6, 29-90 (1986a).
5. + cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor. J. Immunol., 136, 3939-3944 (1986b).
6. BOLHUIS, R.L.H., LAMERS, C.H.J., GOEY, S.H., EGGERMONT, A.M.M., TRIMBOS, J.B.M.Z., STOTER, G., LANZAVECCHIA, A., DI RE, E., MIOTTI, S., RASPAGLIESI, F., RIVOLTINI, L. and COLNAGHI, M.I., Adoptive immunotherapy of ovarian carcinoma with bsmAb-targeted lymphocytes: a multicenter study. Int. J. Cancer, (Suppl. 7), 78-81 (1992).
7. BRAAKMAN, E., GOEDEGEBUURE, P.S., VREUGDENHIL, R.J., SEGAL, D.M., SHAW, S. and BOLHUIS, R.L.H., ICAM-melanoma cells are relatively resistant to CD3-mediated T-cell lysis. Int. J. Cancer, 46, 475-480 (1990).
8. CHONG, A.S.F., JIANG, X.L., SCUDERI, P., LAMAS, M. and GRAF, L.H., JR., ICAM-1 and LFA-3 enhance the ability of anti-CD3 mAb to stimulate interferon gamma production in interleukin-2-activated T cells. Cancer Immunol. Immunother., 39, 127-134 (1994).
9. COLLINS, T.L., KASSNER, P.D., BIERER, B.E. and BUKAKOFF, S.J., Adhesion receptors in lymphocyte activation. Curr. Opin. Immunol., 6, 385-393 (1994).
10. ESHHAR, Z. and GROSS, G., Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach. Brit. J. Cancer, 62, 27-29 (1990).
11. ESHHAR, Z., WAKS, T., GROSS, G. and SCHINDLER, D.G., Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. nat. Acad. Sci. (Wash.), 90, 720-724 (1993).
12. FERRINI, S., SFORZINI, S., CAMBIAGGI, A., POGGI, A., MEAZZA, R., CANEVARI, S., COLNAGHI, M.I. and MORETTA, L., The LFA-1/ICAM cell adhesion pathway is involved in tumor-cell lysis mediated by bispecific monoclonal-antibody-targeted T lymphocytes. Int. J. Cancer, 56, 846-852 (1994).
13. GOEDEGEBUURE, P.S., BRAAKMAN, E., SEGAL, D.M., VREUGDENHIL, R.J. and BOLHUIS, R.L.H., Lymphocyte leukocyte function-associated antigen 1 interacting with target cell intercellular adhesion molecule 1 co-activates cytolysis triggered via CD 16 or the receptor involved in major histocompatibility antigen-unrestricted lysis. Int. Immunol., 2, 1213-1220 (1990).
14. GOROCHOV, G., GROSS, G., WAKS, T. and ESHHAR, Z., Anti-leucocyte function-associated antigen-1 antibodies inhibit T-cell activation following low-avidity and adhesion-independent interactions. Immunology, 79, 548-555 (1993).
15. HEICAPPELL, R., PODLINSKI, J., BUSZELLO, H. and ACKERMANN, R., Cell surface expression and serum levels of intercellular adhesion molecule-1 in renal cell carcinoma. Urol. Res., 22, 9-15 (1994).
16. HWU, P., SHAFER, G.E., TREISMAN, J., SCHINDLER, D.G., GROSS, G., COWHERD, R., ROSENBERG, S.A. and ESHHAR, Z., Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J. exp. Med., 178, 361-366 (1993).
17. KRENSKY, A.M., SANCHEZ-MADKIU, F., ROBBINS, E., NAGY, J.A., SPRINGER, T.A. and BURAKOFF, S.J., The functional significance, distribution and structure of LFA-1, LFA-2 and LFA-3: cell surface antigen associated with CTL-target interactions. J. Immunol., 131, 611-616 (1983).
18. KUSTER, H., THOMPSON, H. and KINET, J.-P., Characterization and expression of the gene for the human Fc receptor gamma subunit. J. biol. Chem., 265, 6448-6452 (1990).
19. LAMERS, C.H.J., VAN DE GRIEND, R.J., BRAAKMAN, E., RONTELTAP, C.P.M., BÉNARD, J., STOTER, G., GRATAMA, J.W. and BOLHUIS, R.L.H., Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy. Int. J. Cancer, 51, 973-979 (1992).
20. LANZAVECCHIA, A. and SCHEIDEGGER, D., The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Europ. J. Immunol., 17, 105-111 (1987).
21. LEEUWENBERG, J., SPITS, H., TAX, W. and CAPEL, P.J.A., Monoclonal antibodies against T3 induce antigen non-specific cellular cytotoxicity. J. Immunol., 134, 3770-3775 (1985).
22. LETOURNEUR, F. and KLAUSNER, R.D., T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc. nat. Acad. Sci. (Wash.), 88, 8905-8909 (1991).
23. LUB, M., VAN KOOYK, Y. and FIGDOR, C.G., Ins and outs of LFA-1. Immunol. Today, 16, 479-483 (1995).
24. MEUER, S.C., HUSSEY, R.E. and FABBI, M., An alternative pathway of T-cell activation: a functional role for the 50 KD T11 sheep erythrocyte receptor protein. Cell, 36, 897-906 (1984).
25. PEREZ, P., HOFFMAN, R.W., SHAW, S., BLUESTONE, J.A. and SEGAL, D.M., Specific targeting of cytotoxic T cells by anti-CD3 linked to anti-target antibody. Nature (Lond.), 316, 354-356 (1985).
26. RENNER, C., JUNG, W., SAHIN, U., VAN LIER, R. and PFREUNDSCHUH, M., The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Europ. J. Immunol., 25, 2027-2033 (1995).
27. + T lymphocytes armed with universal T-cell receptors. Blood, 84, 2878-2889 (1994).
28. ROMEO, C. and SEED, B., Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell, 64, 1037-1046 (1991).
29. ROSENBERG, S.A., YANNELLI, J.R., YANG, J.C., TOPALIAN, S.L., SCHWARTZENTRUBER, D.J., WEBER, J.S., PARKINSON, D.R., SEIPP, C.A., EINHORN, J.H. and WHITE, D.E., Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. nat. Cancer Inst., 86, 1159-1166 (1994).
30. SANTAROSA, M., FAVARO, D., QUAIA, M., SPADA, A., SACCO, C., TALAMINI, R. and GALLIGIONI, E., Expression and release of intercellular adhesion molecule-1 in renal-cancer patients. Int. J. Cancer, 62, 271-275 (1995).
31. SHAW, S., GOLDSTEIN, G., SPRINGER, T.A. and BIDDISON, W.E., Susceptibility of the cytotoxic T lymphocyte (CTL) clones to inhibition by anti-T3 and anti-T4 (but not anti-LFA-1) monoclonal antibodies varies with the "avidity" of the CTL-target interaction. J. Immunol., 134, 3019-3026 (1985).
32. SPRINGER, T.A., Adhesion receptors of the immune system. Nature (Lond.), 346, 425-434 (1990).
33. + killer cell clones by monoclonal antibodies (anti-CD 16, anti-CD2, anti-CD3) depends on sub class specificity of target cell IgG-FcR. J. Immunol., 138, 3137-3144 (1987).
34. VAN DE GRIEND, R.J., GIPHART, M.J., VAN KRIMPEN, B.A. and BOLHUIS, R.L.H., Human T cell clones exerting multiple cytolytic activities show heterogeneity in susceptibility to inhibition by monoclonal antibodies. J. Immunol., 133, 1222-1229 (1984a).
35. VAN DE GRIEND, R.J., VAN KRIMPEN, B.A., RONTELTAP, C.P.M. and BOLHUIS, R.L.H., Rapidly expanded activated human killer cell clones have strong antitumor cell activity and have the surface phenotype of either Tτ, T-non-τ, or null cells. J. Immunol., 132, 3185-3191 (1984b).
36. VAN DIJK, J., WARNAAR, S.O., VAN EENDENBURG, J.D.H., THIENPONT, M., BRAAKMAN, E., BOOT, J.H.A., FLEUREN, G.J. and BOLHUIS, R.L.H., Induction of tumor cell lysis by bi-specific monoclonal antibodies recognizing renal cell carcinoma and CD3 antigen. Int. J. Cancer, 43, 344-349 (1989).
37. VAN WAUWE, J.P., DE MEY, J.R. and GOOSSENS, J.G., OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J. Immunol., 124, 2708-2713 (1980).
38. WEIJTENS, M.E.M., WILLEMSEN, R.A., VALERIO, D., SIAM, K. and BOLHUIS, R.L.H., Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle their lytic capacity. J. Immunol., 157, 836-843 (1996).